Papillary Epithelial Neoplasm

cancer family

Identifier: CI-CAN-00000311
Entity page: /cancer/papillary-epithelial-neoplasm ↗
Edges: 566

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Papillary Epithelial Neoplasm altered in cohorts of …ALTERED_INderived15 of 205show all (up to 200)
← altered in cohorts of	HELZ 187 / 291 cases (64 %) · ssm · TCGA-KIRP	—	—	Papillary Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MED13 187 / 291 cases (64 %) · ssm · TCGA-KIRP

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRAF V600E Vemurafenib2 active / 3 trials
Curatedlevel Bsensitivity· support 3civicObservedBRAF altered in 59% (293 / 496 cases, largest of 4 cohorts)no approval record in this cancercontext: Thyroid Gland Papillary Carcinoma
MET Mutation Foretinib0 active / 0 trials
Curatedlevel Bsensitivity· support 1civicObservedMET altered in 7.4% (21 / 282 cases, largest of 3 cohorts)no approval record in this cancercontext: Papillary Renal Cell Carcinoma
RET Fusion SelpercatinibFDA US 2020-05-08 · tumour-agnostic3 active / 4 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerRegulatoryapproved (3 approval records)context: Thyroid Gland Papillary Carcinoma
NTRK1 Fusion LarotrectinibFDA US 2018-11-26 · tumour-agnostic0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NTRK1 in this cancerRegulatoryapproved (3 approval records)context: Thyroid Gland Papillary Carcinoma
NTRK1 Fusion LarotrectinibFDA US 2018-11-26 · tumour-agnostic0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NTRK1 in this cancerRegulatoryapproved (3 approval records)context: Thyroid Gland Papillary Carcinoma
NTRK1 Fusion LarotrectinibFDA US 2018-11-26 · tumour-agnostic0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NTRK1 in this cancerRegulatoryapproved (3 approval records)context: Thyroid Gland Papillary Carcinoma
NTRK3 Fusion EntrectinibEMA EU 2020-07-311 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NTRK3 in this cancerRegulatoryapproved for Lung Non-Small Cell Carcinoma (3 approval records)context: Thyroid Gland Papillary Carcinoma
RET Overexpression Sunitinib2 active / 5 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for RET in this cancerno approval record in this cancercontext: Papillary Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Papillary Epithelial Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 80show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 14 trials (6 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 12 trials (8 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 12 trials (6 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 8 trials (8 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenib Tosylatesmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Papillary Epithelial Neoplasm	5	Observed	clinicaltrials	graph →

Papillary Epithelial Neoplasm studied in …STUDIED_INderived10 of 281show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 281 trials mapped (102 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05712356Phase 2 · completed A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Gallbladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07024680completed Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05575440terminated Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Thyroid Gland Papillary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07146646Phase 2 · recruiting Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Gallbladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03635892Phase 2 · active not recruiting A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · condition mapped ALIAS · 281 trials mapped (102 active)	—	—	Thyroid Gland Papillary Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05797246Phase 2 · active not recruiting Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · condition mapped ONTOLOGY_EXACT · 281 trials mapped (102 active)	—	—	Papilloma	1	Observed	clinicaltrials	graph →